790223-65-3

Basic information

• Product Name: 1-(TETRAHYDRO-PYRAN-4-YL)-PIPERAZINE DIHYDROCHLORIDE
• Synonyms: 1-(TETRAHYDRO-PYRAN-4-YL)-PIPERAZINE DIHYDROCHLORIDE;1-(Tetrahydro-2H-pyran-4-yl)-piperazine 2HCl
• CAS NO: 790223-65-3
• Molecular Formula: C9H18N2O.2ClH
• Molecular Weight: 243.176
• Mol File: 790223-65-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(TETRAHYDRO-PYRAN-4-YL)-PIPERAZINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(TETRAHYDRO-PYRAN-4-YL)-PIPERAZINE DIHYDROCHLORIDE(790223-65-3)
• EPA Substance Registry System: 1-(TETRAHYDRO-PYRAN-4-YL)-PIPERAZINE DIHYDROCHLORIDE(790223-65-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 790223-65-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(TETRAHYDRO-PYRAN-4-YL)-PIPERAZINE DIHYDROCHLORIDE is used as a psychoactive agent for the treatment of psychosis and mental disorders. Its properties make it a promising candidate for pharmaceutical formulations.
Used in Research and Experimental Studies:
1-(TETRAHYDRO-PYRAN-4-YL)-PIPERAZINE DIHYDROCHLORIDE is used as a research compound to investigate its potential in treating various neurological and psychiatric conditions. Its dihydrochloride salt form increases its solubility and stability, making it more suitable for experimental studies.

Upstream product

• 706759-32-2 4-(tetrahydro-2H-pyran-4-yl)piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1410854-54-4 4-[4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl]aniline 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM

The present invention describes compounds with formula (I) having linear structure basic properties useful as NK-2 antagonists; pharmaceutical compositions containing said compounds are also described and processes for their preparation.